With a combined integrative and bioinformatics approach, we identified the dysregulation in the cell cycle pathway and predicted the activation of NEK2 and AURKA across breast cancer, colon cancer, LUAD, ovarian cancer, and UCEC. This evidence concerns the gene AURKA and breast carcinoma.